Yarrow Bioscience (YARW) Other Non-Current Liabilities (2016 - 2024)
Yarrow Bioscience's (YARW) quarterly Other Non-Current Liabilities came in at $1.3 million in Q1 2024, little changed YoY from $1.3 million in Q2 2023, and down 0.99% on a QoQ basis from $1.3 million in Q4 2023.
Yarrow Bioscience (YARW) Other Non-Current Liabilities (2016 - 2024) Analysis & Trends
Yarrow Bioscience (YARW) has 8 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q1 2024.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $1.3 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $1.3 million (changed 0.0% YoY) and the FY2023 annual result came in at $1.3 million, changed N/A from the prior year.
- Other Non-Current Liabilities fell to $1.3 million in Q1 2024, from $1.3 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.3 million in Q4 2023 to a low of $451000.0 in Q3 2021.
- A 4-year average of $808250.0 and a median of $457000.0 in 2020 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Other Non-Current Liabilities advanced 0.22% — and 2021, when it decreased 1.31%.
- Tracing YARW's Other Non-Current Liabilities over 4 years: stood at $457000.0 in 2020, then slipped by 1.31% to $451000.0 in 2021, then jumped by 191.13% to $1.3 million in 2023, then fell by 0.99% to $1.3 million in 2024.
- The last three Other Non-Current Liabilities figures came in at $1.3 million (Q1 2024), $1.3 million (Q4 2023), and $1.3 million (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.30 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Sep 30, 2023 | 1.30 Mn |
| Jun 30, 2023 | 1.30 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Sep 30, 2021 | 451,000.00 |
| Jun 30, 2021 | 452,000.00 |
| Mar 31, 2021 | 457,000.00 |
| Dec 31, 2020 | 457,000.00 |
| Sep 30, 2020 | 457,000.00 |
| Jun 30, 2020 | 456,000.00 |
| Mar 31, 2020 | 456,000.00 |
| Dec 31, 2019 | 456,000.00 |
| Dec 31, 2018 | 7,000.00 |
| Sep 30, 2018 | 12,000.00 |
| Jun 30, 2018 | 78,000.00 |
| Mar 31, 2018 | 20,000.00 |
| Dec 31, 2017 | 22,000.00 |
| Dec 31, 2016 | 57,000.00 |